莫德纳（Moderna, Inc.）周三盘后股价大跌5.4%，主要原因是该公司宣布其实验性巨细胞病毒（CMV）疫苗在三期临床试验中未能达到主要疗效指标。
据报道，莫德纳公司在约7500名16至40岁女性中进行的三期临床试验显示，其mRNA-1647疫苗的有效率仅为6%到23%之间，远低于公司预期目标。这一结果导致莫德纳宣布终止该CMV疫苗的研发。莫德纳公司总裁斯蒂芬·霍格表示："我们对未能预防原发性感染感到失望，这意味着尽管该领域已开展了数十年的工作，但仍然没有预防先天性巨细胞病毒的疫苗。"
尽管遭遇这一重大研发挫折，莫德纳表示不预计其2025年财务指引或2028年实现盈亏平衡的预期受到任何影响。公司还表示将继续在进行中的第二阶段临床试验中评估MRNA-1647在骨髓移植患者中的应用。然而，这一消息仍然对投资者信心造成了显著打击，导致股价在盘后交易中大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.